Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …

Epithelial–mesenchymal transition (EMT) is a program wherein epithelial cells lose their
junctions and polarity while acquiring mesenchymal properties and invasive ability …

Organoids have immense potential as ex vivo disease models for drug discovery and
personalized drug screening. Dynamic changes in individual organoid morphology, number …

Long noncoding RNAs (lncRNA) play an important role in gene regulation in both normal
tissues and cancer. Targeting lncRNAs is a promising therapeutic approach that has …

Organ-on-a-Chip (OOC) technology, which emulates the physiological environment and
functionality of human organs on a microfluidic chip, is undergoing significant technological …

Breast cancer is one of the common malignancies with poor prognosis worldwide. The
treatment of breast cancer patients includes surgery, radiation, hormone therapy …

Organoids are miniaturized and simplified versions of an organ produced in vitro from stem
or progenitor cells. They are used as a model system consisting of multiple cell types …

The traditional view of cancer emphasizes a genes-first process. Novel cancer traits arise by
genetic mutations that spread to drive phenotypic change. However, recent data support a …

Measuring single cell responses to the universe of chemicals (drugs, natural products,
environmental toxicants etc.) is of paramount importance to human health as phenotypic …

An accumulation of previous work has established organoids as good preclinical models of
human tumors, facilitating translation from basic research to clinical practice. They are …